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Edited by Varda RotterAbstract Protein transduction therapy using poly-arginine can
deliver the bioactive p53 protein into cancer cells and inhibits
the proliferation of the cells. However, one disadvantage of such
therapy is the short intracellular half-life of the delivered protein.
Here, we generated mutant proteins in which multiple lysine res-
idues in the C-terminal were substituted by arginines. The mu-
tant proteins were eﬀectively delivered in glioma cells and were
resistant to Mdm2-mediated ubiquitination. Moreover, the mu-
tant proteins displayed higher transcription regulatory activity
and powerful inhibition of the proliferation of glioma cells. These
results suggest that ubiquitination-resistant p53 protein therapy
may become a new eﬀective cancer therapy.
 2005 Published by Elsevier B.V. on behalf of the Federation of
European Biochemical Societies.
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p531. Introduction
Protein transduction domains (PTDs) such as that in TAT
protein from HIV-1 are capable of mediating the transfer of
proteins across the plasma membrane into nearly all eukary-
otic cells [1,2]. Poly-arginine (6–12 residues) also has the same
transduction activity as the PTDs [3–5]. PTDs have become
widely used as tools for the delivery of proteins into cells in
culture, and even into the tissues of living animals [6].
Recent advances in molecular oncology have led to the iden-
tiﬁcation of proteins that are quantitatively, qualitatively or
genetically altered in cancer cells. P53 protein is one of the al-
tered proteins in cancer cells, and is mutated or deleted in more
than half of human tumors [7]. Eleven poly-arginine-fused
wild-type p53 protein (11R-p53) eﬀectively penetrates across
the plasma membrane and inhibits the proliferation of human
cancer cells [8]. However, the half-life of 11R-p53 is less thanAbbreviations: HIV-1, human immunodeﬁciency virus type-1
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for the inhibition of cancer cell proliferation [8]. The develop-
ment of protein therapy to transduce stable proteins or of
methods to stabilize the delivered proteins is important for
the initiation of clinical trials of protein therapy.
Previous studies have shown that the COOH-terminal region
of p53 modulates the susceptibility of p53 to Mdm2-mediated
degradation [9–11]. p53 mutant in which lysine residues 370,
372, 373, 381, 382 and 386 in the COOH-terminal are replaced
by arginine residues is resistant to ubiquitin-proteosome-
mediated degradation, and its transcriptional activity was
higher than that of wild-type p53 [9]. In the present study,
we developed a new protein transduction therapy with mu-
tated p53 protein by substituting multiple lysine residues with
arginine and investigated the eﬀect of the substitution on the
stability of the protein and the ability of the protein to inhibit
the growth of malignant glioma cells.2. Materials and methods
2.1. Cell lines and cell culture
The human malignant glioma cell lines A172, U251-MG and T98G
were provided by Health Science Research Resources Bank (Osaka,
Japan). The malignant glioma cell line KR158 was a gift from Dr. T
Jacks (MIT). All cell lines were maintained in DMEM (Invitrogen)
supplemented with 10% fetal bovine serum, 100 U/ml penicillin and
100 U/ml streptomycin. The cells were cultured in a 37 C incubator
with 5% CO2.
Rat primary astrocytes were prepared from postnatal day 1 newborn
Wistar rats (Japan SLC Inc.).2.2. Site-directed mutagenesis of human p53 cDNA and the structure
of 11R-p53
Human wild-type p53 cDNA was subcloned into p11R-HA vector
(Supplementary Fig. 1A, Ref. [8]). The multiple lysine-to-arginine mu-
tants of the p53 cDNA were generated by site-directed mutagenesis
using a PCR strategy as described previously [12]. In the 3KR-p53 mu-
tant, the lysine residues at 381, 382, and 386 were changed to arginine
and in the 6KR-p53 mutant, the six lysine residues at 370, 372, 373,
381, 382, and 386 were changed to arginine (Supplementary Fig. 1B).
2.3. Puriﬁcation of 11R-p53 fusion protein
Puriﬁcation of 11R-p53 proteins was performed as described previ-
ously [8]. There was no diﬀerence in the expression or the purity among
the proteins (Supplementary Fig. 1C).ation of European Biochemical Societies.
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The recombinant adenoviruses (pAdex-p53) were then puriﬁed and
concentrated using the CsCl step-gradient method as described previ-
ously [8].
2.5. Western blotting analysis
Western blotting analysis for p53 was carried out at high
stringency, essentially as described previously [13]. The blots were
probed with primary antibodies against p53 (1:1000; Pab 1801;
Santa Cruz Biotechnology, Inc.) and p21 (1:1000; H-164; Santa
Cruz Biotechnology).
2.6. Detection of the ubiquitination of 11R-p53 proteins
A172 cells and U251-MG cells were incubated with 100 nM WT-
p53, 3KR-p53, or 6KR-p53 for 12 h in the presence or absence of
25 lM MG132, a proteasome inhibitor. Whole-cell extracts (100 lg
of protein) were analyzed by Western blotting analysis with anti-p53
antibody (Pab 1801; Santa Cruz Biotechnology).2.7. Reporter assay for p53-driven transactivation
The reporter assay was performed as described previously [8].
2.8. Cell viability assay
Cell viability was determined using a WST-1 (2-[2-methoxy-4-nitro-
phenyl]-3-[4-nitrophenyl]-5-[2, 4-disulfophenyl]-2H-tetrazolium, mono
sodium salt) assay (Roche Applied Science) as described previously [8].
2.9. TUNEL assay
The TUNEL assay was performed following the protocol of the
TUNEL kits manufacturer (Roche Diagnostics). Before assessment,
U251-MG cells were treated with each 11R-p53 at 0.1 lM for 24 h.
Representative graphs are shown for experiments in which at least 6
randomly chosen ﬁelds with 50 cells were scored.
2.10. Statistical analysis
Data are shown as the mean (±S.E.M.). Data were analyzed using
either Students t test to compare two conditions or ANOVA followed
by planned comparisons of multiple conditions, and P < 0.05 was con-
sidered to be signiﬁcant.Fig. 1. (A) Time-dependent degradation of WT-p53, 3KR-p53 and
6KR-p53 in malignant glioma cell lines, A172 (upper panel), U251
(middle panel) and T98G (lower panel). Cont., no transduction of any
protein. As a control, A172 cells were infected with recombinant
adenovirus of wild-type p53 (pAdex-p53) at MOI 100. (B) Comparison
of the levels of WT-p53, 3KR-p53 and 6KR-p53 48 h after protein
transduction in each malignant glioma cell line. Data are represented
as % of the level 12 h after each protein transduction and are the
means ± S.E.M. of four independent experiments. \, P < 0.01 and
\\, P < 0.05 vs. WT-p53.3. Results
3.1. Long-term maintenance of 6KR-p53 and 3KR-p53 in
malignant glioma cell lines
Three malignant glioma cell lines, A172, U251-MG and
T98G, were incubated with 100 nM poly-arginine-fused wild-
type p53 protein (WT-p53) or two kinds of mutant p53 pro-
teins (3KR-p53 and 6KR-p53) for 4 h and then washed with
PBS three times. A high level of WT-p53 was detected 12 h
after the protein transduction in all three cell lines, but the level
was rapidly decreased by 24 h (Fig. 1A). WT-p53 was unde-
tectable in U251-MG and T98 cells at 24 h and in A172 cells
48 h after the protein transduction (Fig. 1A and B). In con-
trast, both 3KR-p53 and 6KR-p53 were maintained at a high
level 24 h after the protein transduction in all three cell lines
(Fig. 1A). The residual levels of 3KR-p53 and 6KR-p53 48 h
after the protein transduction were signiﬁcantly higher than
that of WT-p53 in all cell lines (Fig. 1B, n = 4 each,
\P < 0.01, \\P < 0.05 vs. WT-p53). These results suggest that
both 3KR and 6KR are resistant to degradation in malignant
glioma cells.
3.2. Resistance of 6KR-p53 to ubiquitination
A172 cells were transduced with 100 nM WT-p53, 3KR-p53
or 6KR-p53 in the presence of a proteasome inhibitor,MG132, and the cells were harvested 12 h after the transduc-
tion and subjected to Western blotting analysis using anti-
p53 antibody. In the WT-p53-transduced A172 cells, forms
of p53 whose migration was consistent with ubiquitination
were observed (Fig. 2A). In the 6KR-p53-transduced cells,
the slower migrating forms of p53 were virtually eliminated
(Fig. 2A). In the WT-p53 transduced U251-MG cells, slower
migrating forms of p53 were not observed in the absence of
MG132, whereas signiﬁcant amounts of the slower migrating
forms were generated in the presence of MG132 (Fig. 2B). In
the 6KR-p53-transduced cells, slower migrating forms of p53
were not detected in the presence or absence of MG132
(Fig. 2B). These results suggest that the 6KR-p53 protein with
mutation of the COOH-terminal six lysine residues is resistant
to poly-ubiquitination.
Fig. 3. (A) Time-dependent changes of the transcription regulatory
activity of WT-p53, 3KR-p53 and 6KR-p53 in KR158 cells. A
luciferase reporter vector carrying the p21/WAF1 promoter was
transfected into KR158 cells. After 24 h, the cells were either
transduced with each type of 11R-p53 at 100 nM or were infected
with pAdex-p53 at MOI 100. As a control (Cont.), the cells were only
transfected with the luciferase reporter vector. n = 6 in each group.
\, P < 0.05 and \\, P < 0.01. (B) Eﬀect of transduction of each 11R-p53
protein on endogenous p21 expression. U251-MG cells were trans-
duced with 100 nM WT-p43, 3KR-p53 or 6KR-p53. The cells were
harvested 48 h after protein transduction and Western blotting
analysis using anti-p21antibody was performed. Cont., no protein
transduction.
Fig. 2. Ubiqutination of each type of 11R-p53 in A172 (A) and U251-
MG (B) cells. (A) A172 cells were incubated with 100 nM WT-p53,
3KR-p53 or 6KR-p53 for 12 h in the presence of 25 lMMG-132. The
whole-cell extracts were resolved by SDS–PAGE and Western blotting
analysis was performed with anti-p53 antibody. As a control, 10 ng of
puriﬁed WT-p53 was electrophoresed on the same gel (puriﬁed WT-
p53). (B) U251-MG cells were incubated with 100 nM WT-p53 or
6KR-p53 for 12 h in the presence or absence of 25 lMMG-132. Intact,
no protein tranduction.
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of 6KR-p53 in KR158 cells
KR158 cells, which lack endogenous p53, were transfected
with a p53-responsive reporter plasmid.After 24 h, the cells were
transduced with 100 nM WT-p53, 3KR-p53 or 6KR-p53. As a
positive control, the cells were infectedwith recombinant adeno-
viruses carrying the wild-type p53 gene (pAdex-p53) at an MOI
of 100. Twenty-four hours after protein transduction, the p53
transcription regulatory activity showed no diﬀerence among
WT-p53-, 3KR-p53- and 6KR-p53-transduced cells (Fig. 3A).
The transcription regulatory activity of 3KR-p53 and 6KR-
p53 was signiﬁcantly higher than that of WT-p53 36 h after
protein transduction (Fig. 3A). Moreover, transduction of
6KR-p53 resulted in maintenance of higher p53 activity after
48 h compared with transduction of WT-p53 (Fig. 3A).
We next examined whether transduction of each p53 protein
induced endogenous p21 expression. The expression level of
p21 was very low in U251-MG cells (Fig. 3B). WT-p53 protein
transduction slightly induced the expression of endogenous
p21 in the cells (Fig. 3B). 3KR-p53 was more eﬀective for
inducing p21 expression. In the 6KR-p53 transduced cells,
endogenous p21 expression was most prominent (Fig. 3B).
These results suggest that 6KR-p53 has higher and longer-
lasting p53 transcription regulatory activity compared with
WT-p53 in malignant glioma cells.3.4. Inhibition of the growth of malignant glioma cell lines by
administration of 6KR-p53
A previous study showed that a single administration of
100 nM WT-p53 failed to inhibit the growth of oral cancer
cells (8). In the present study, the inhibitory eﬀect of a single
transduction of WT-p53, 3KR-p53 or 6KR-p53 on the prolif-
eration of malignant glioma cell lines was investigated. T98G
(Fig. 4A), U251-MG (Fig. 4B) and A172 (Fig. 4C) cells were
incubated with various concentrations of WT-p53, 3KR-p53
or 6KR-p53 for 2 h. After the cells were washed with PBS, they
were replaced in fresh medium in the absence of 11R-p53. The
cell viability was assessed by the WST-1 assay 2 h (Day 0) and
Fig. 5. Comparison of the eﬀect of each protein transduction on the
induction of apoptosis of U251-MG cells. U251-MG cells were
transduced with 100 nM WT-p53, 3KR-p53 or 6KR-p53. After 24 h,
the cells were stained with TUNEL and TUNEL-positive cells were
counted. Representative graphs are shown for experiments in which at
least 6 randomly chosen ﬁelds with 50 cells were scored. \, P < 0.001.
Fig. 4. Comparison of the eﬀect of a single transduction of each type
of 11R-p53 on the growth of malignant glioma cell lines, T98G (A),
U251-MG (B) and A172 (C) 96 h after protein transduction. The cells
were transduced with various concentrations of WT-p53, 3KR-p53 or
6KR-p53 on Day 0 and were cultured for 96 h (Day 4). Cell viability
was measured by the WST-1 assay on Day 0 and Day 4. Cont.; no
protein transduction. Data are presented as the means; n = 8 in each
group; bars, S.E.M. \, P < 0.01 and \\, P < 0.05 compared with the
untreated cells of each cell line.
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WT-p53 (1–100 nM) did not inhibit the cell growth of any of
the cell lines (Fig. 4A–C). In the T98G cells, 100 nM 3KR-
p53 signiﬁcantly inhibited the proliferation (Fig. 4A). How-
ever, all tested concentrations of 3KR-p53 failed to inhibit
the cell growth of U251-MG and A172 cell lines (Fig. 4B
and C). In contrast, 100 nM 6KR-p53 signiﬁcantly inhibited
the growth of all cell lines 96 h after the protein transduction
compared with the growth of control cells (Fig. 4A–C) but 1
and 10 nM 6KR-p53 did not aﬀect the growth of any of the
cell lines.
We further examined whether 6KR-p53 protein transduc-
tion induced the apoptosis of malignant glioma cells. U251-
MG cells were treated with 100 nM WT-p53, 3KR-p53 or
6KR-p53 for 24 h and apoptotic cells were assessed by TU-
NEL staining. The eﬀect of WT-p53 on the induction ofapoptosis was slight and the eﬀect of 3KR-p53 protein trans-
duction was not diﬀerent from that of WT-p53 (Fig. 5). In con-
trast, 6KR-p53 signiﬁcantly induced apoptosis of malignant
glioma cells compared with WT-p53 (Fig. 5).
The transduction of 3KR-p53 and 6KR-p53 did not inhibit
the growth of primary astrocytes or induce the apoptosis of the
cells, whereas recombinant adenovirus carrying the wild-type
p53 gene at an MOI of 500 signiﬁcantly induced apoptosis
and inhibited the cell growth of primary astrocytes (Fig. 6).4. Discussion
Advanced-stage carcinomatosis is often resistant to current
chemotherapy treatment, and new strategies for treating the
disease are clearly needed [14]. It has been thought that gene
therapy with viral vectors and non-viral vectors may be an
attractive tool to treat cancer [15]. However, a large number
of studies have indicated that virus-mediated gene therapy
has some safety problems, such as inﬂammatory response, tox-
icity of the virus vector itself and random integration of virus
vector DNA into the host chromosomes [16,17]. Similarly,
non-virus vectors also have a problem of the eﬃciency of gene
transduction at present [16]. In the last few years, a number of
protein transduction therapies have been tried for treating can-
cer in vitro and in an experimental murine model [5,8,18].
These studies have shown that protein transduction therapy
is useful for the delivery of tumor suppressor proteins, peptides
and drugs and eﬀective for the inhibition of cancer growth.
However, the transduced proteins and peptides show limited
stability; for example, poly-arginine-fused wild-type p53 pro-
tein (11R-p53) is rapidly degraded in cancer cells [8]. In the
present study, we generated 11R-p53 mutants (3KR-p53 and
6KR-p53), in which multiple lysine residues in the COOH-ter-
minal region were substituted by arginines. The mutant pro-
teins were resistant to ubiquitination and were maintained
longer than 11R-p53 in glioma cell lines, and the anti-tumor
eﬀect of the transduction of the mutant proteins was main-
tained longer than that of 11R-p53. Moreover, the anti-tumor
Fig. 6. Eﬀect of WT-p53, 3KR-p53 and 6KR-p53 on the growth and
apoptosis of normal glial cells. Rat primary astrocytes were transduced
with 100 nM WT-p53, 3KR-p53 or 6KR-p53. (A) The WST assay was
performed 4 days after protein transduction. Cont.; no protein
transduction. As a control, the cells were infected with recombinant
adenovirus carrying the wild-type p53 gene at an MOI of 500. n = 8 in
each group. P < 0.001. (B) Quantitative analysis of the TUNEL-
positive cells. TUNEL staining was performed 24 h after protein
transduction. n = 8 in each group. P < 0.001.
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p53. These results suggest that the six lysine residues in the
COOH terminal of p53 are the main sites of ubiquitin ligation,
which targets p53 for proteasome-mediated degradation,
and indicate that protein transduction therapy of ubiquitin-
proteasome-mediated-degradation- resistant p53 proteins such
as 6KR-p53 may avoid the disadvantages of p53 protein trans-
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